## D Regan

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3780878/publications.pdf

Version: 2024-02-01

279701 223716 2,204 68 23 46 citations h-index g-index papers 70 70 70 2267 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of <i>Neisseria gonorrhoeae</i> Infection Among Urban Men Who Have Sex With Men. Journal of Infectious Diseases, 2022, 225, 983-993.	1.9	20
2	Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004–18. Lancet Infectious Diseases, The, 2021, 21, 1747-1756.	4.6	17
3	Genital warts trends in Australian and overseas-born people in Australia: A cross-sectional trend analysis to measure progress towards control and elimination. The Lancet Regional Health - Western Pacific, 2021, 16, 100251.	1.3	1
4	Effect of a School-Based Educational Intervention About the Human Papillomavirus Vaccine on Psychosocial Outcomes Among Adolescents. JAMA Network Open, 2021, 4, e2129057.	2.8	12
5	Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia. PLoS Computational Biology, 2021, 17, e1009385.	1.5	O
6	Supplemental Trichomonas vaginalis testing is required to maintain control following a transition from Pap smear to HPV DNA testing for cervical screening: a mathematical modelling study. Sexually Transmitted Infections, 2020, 96, 76-78.	0.8	1
7	Defining Elimination of Genital Warts—A Modified Delphi Study. Vaccines, 2020, 8, 316.	2.1	1
8	Factors Associated With Early Resumption of Condomless Anal Sex Among Men Who Have Sex With Men After Rectal Chlamydia Treatment. Sexually Transmitted Diseases, 2020, 47, 389-394.	0.8	4
9	Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014–2017. Vaccine, 2019, 37, 6907-6914.	1.7	18
10	Modelling the in-host dynamics of <i>Neisseria gonorrhoeae </i> infection. Pathogens and Disease, 2019, 77, .	0.8	4
11	Modelling the decline and future of hepatitis A transmission in Australia. Journal of Viral Hepatitis, 2019, 26, 199-207.	1.0	5
12	A reliable and easy to transport quality control method for chlamydia and gonorrhoea molecular point of care testing. Pathology, 2018, 50, 317-321.	0.3	4
13	Impact of replacing cytology with human papillomavirus testing for cervical cancer screening on the prevalence of <i>Trichomonas vaginalis</i> : a modelling study. Sexually Transmitted Infections, 2018, 94, 216-221.	0.8	5
14	Molecular point-of-care testing for chlamydia and gonorrhoea in Indigenous Australians attending remote primary health services (TTANGO): a cluster-randomised, controlled, crossover trial. Lancet Infectious Diseases, The, 2018, 18, 1117-1126.	4.6	26
15	Treatment for pharyngeal gonorrhoea under threat. Lancet Infectious Diseases, The, 2018, 18, 1175-1177.	4.6	9
16	Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. Lancet, The, 2018, 392, 1413-1422.	6.3	63
17	Molecular test for chlamydia and gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic test evaluation. Sexually Transmitted Infections, 2018, 94, 340-345.	0.8	39
18	Identifying factors that lead to the persistence of importedgonorrhoeaestrains: a modelling study. Sexually Transmitted Infections, 2017, 93, 221-225.	0.8	4

#	Article	IF	CITATIONS
19	Treatment efficacy of azithromycin 1Âg single dose versus doxycycline 100Âmg twice daily for 7Âdays for the treatment of rectal chlamydia among men who have sex with men – a double-blind randomised controlled trial protocol. BMC Infectious Diseases, 2017, 17, 35.	1.3	18
20	Early sexual experiences of teenage heterosexual males in Australia: a cross-sectional survey. BMJ Open, 2017, 7, e016779.	0.8	6
21	Neisseria gonorrhoeae Transmission Among Men Who Have Sex With Men: An Anatomical Site-Specific Mathematical Model Evaluating the Potential Preventive Impact of Mouthwash. Sexually Transmitted Diseases, 2017, 44, 586-592.	0.8	54
22	Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia. Vaccine, 2017, 35, 5228-5234.	1.7	4
23	Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective. Vaccine, 2017, 35, 4923-4929.	1.7	38
24	Molecular Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae, Northern Territory, Australia. Emerging Infectious Diseases, 2017, 23, 1478-1485.	2.0	27
25	Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Medical Journal of Australia, 2017, 206, 204-209.	0.8	33
26	Changes in the rates of Neisseria gonorrhoeaeantimicrobial resistance are primarily driven by dynamic fluctuations in common gonococcal genotypes. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw452.	1.3	8
27	Balancing the cost–benefit equation for cervical cancer prevention: a moving target. Lancet Public Health, The, 2016, 1, e42-e43.	4.7	2
28	Estimating the critical immunity threshold for preventing hepatitis A outbreaks in men who have sex with men. Epidemiology and Infection, 2016, 144, 1528-1537.	1.0	54
29	The Molecular Epidemiology and Antimicrobial Resistance of Neisseria gonorrhoeaein Australia: A Nationwide Cross-Sectional Study, 2012. Clinical Infectious Diseases, 2016, 63, 1591-1598.	2.9	32
30	Real-time PCR detection of <i>Neisseria gonorrhoeae </i> susceptibility to penicillin. Journal of Antimicrobial Chemotherapy, 2016, 71, 3090-3095.	1.3	9
31	P066â€Transmission ofNeisseria Gonorrhoeaeamong men who have sex with men: an anatomical site-specific mathematical model and impact of mouthwash. Sexually Transmitted Infections, 2016, 92, A41.2-A41.	0.8	0
32	A real-time PCR assay for direct characterization of the <i>Neisseria gonorrhoeae </i> GyrA 91 locus associated with ciprofloxacin susceptibility. Journal of Antimicrobial Chemotherapy, 2016, 71, 353-356.	1.3	28
33	Varicella-Zoster Virus in Perth, Western Australia: Seasonality and Reactivation. PLoS ONE, 2016, 11, e0151319.	1.1	20
34	Chlamydia and gonorrhoea point-of-care testing in Australia: where should it be used?. Sexual Health, 2015, 12, 51.	0.4	4
35	HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents. BMC Public Health, 2015, 15, 896.	1.2	17
36	Exploring the Benefits of Molecular Testing for Gonorrhoea Antibiotic Resistance Surveillance in Remote Settings. PLoS ONE, 2015, 10, e0133202.	1.1	9

#	Article	IF	CITATIONS
37	Multitarget PCR Assay for Direct Detection of Penicillinase-Producing Neisseria gonorrhoeae for Enhanced Surveillance of Gonococcal Antimicrobial Resistance. Journal of Clinical Microbiology, 2015, 53, 2706-2708.	1.8	10
38	Public health implications of molecular point-of-care testing for chlamydia and gonorrhoea in remote primary care services in Australia: a qualitative study. BMJ Open, 2015, 5, e006922-e006922.	0.8	16
39	Oral and anal sex are key to sustaining gonorrhoea at endemic levels in MSM populations: a mathematical model. Sexually Transmitted Infections, 2015, 91, 365-369.	0.8	67
40	Periodicity of varicella-zoster virus in the presence of immune boosting and clinical reinfection with varicella. Theoretical Biology and Medical Modelling, 2015, 12, 6.	2.1	2
41	Greatest effect of HPV vaccination from school-based programmes. Lancet Infectious Diseases, The, 2015, 15, 497-498.	4.6	4
42	Direct real-time PCR-based detection of <i>Neisseria gonorrhoeae </i> 23S rRNA mutations associated with azithromycin resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv274.	1.3	30
43	Increasing hepatitis A immunity in men who have sex with men in Sydney, 1996–2012. Vaccine, 2015, 33, 4745-4747.	1.7	8
44	High-throughput informative single nucleotide polymorphism-based typing of Neisseria gonorrhoeae using the Sequenom MassARRAY iPLEX platform. Journal of Antimicrobial Chemotherapy, 2014, 69, 1526-1532.	1.3	51
45	Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nature Reviews Microbiology, 2014, 12, 223-229.	13.6	100
46	The potential impact of HPV-16 reactivation on prevalence in older Australians. BMC Infectious Diseases, 2014, 14, 312.	1.3	9
47	Could point-of-care testing be effective for reducing the prevalence of trichomoniasis in remote Aboriginal communities?. Sexual Health, 2014, 11, 370.	0.4	0
48	Population movement can sustain STI prevalence in remote Australian indigenous communities. BMC Infectious Diseases, 2013, 13, 188.	1.3	16
49	Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infectious Diseases, 2013, 13, 140.	1.3	81
50	The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models. BMC Infectious Diseases, 2013, 13, 83.	1.3	1
51	Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. Vaccine, 2013, 31, 1931-1936.	1.7	8
52	A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the "TTANGO―trial protocol. BMC Infectious Diseases, 2013, 13, 485.	1.3	38
53	Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, The, 2013, 346, f2032-f2032.	3.0	363
54	Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus. Statistics in Medicine, 2013, 32, 1917-1953.	0.8	14

#	Article	IF	CITATIONS
55	Near Elimination of Genital Warts in Australia Predicted With Extension of Human Papillomavirus Vaccination to Males. Sexually Transmitted Diseases, 2013, 40, 833-835.	0.8	41
56	Modeling the Impact of Treatment Failure on Chlamydia Transmission and Screening. Sexually Transmitted Diseases, 2013, 40, 700-703.	0.8	3
57	The potential impact of new generation molecular point-of-care tests on gonorrhoea and chlamydia in a setting of high endemic prevalence. Sexual Health, 2013, 10, 348.	0.4	34
58	Population benefits of HPV vaccination for boys: a complex equation. Evidence-Based Medicine, 2012, 17, 118-119.	0.6	0
59	Geographical clustering of anal cancer incidence in Australia. Sexual Health, 2012, 9, 509.	0.4	8
60	Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infectious Diseases, The, 2011, 11, 39-44.	4.6	339
61	Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. Sexual Health, 2010, 7, 368.	0.4	8
62	Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theoretical Biology and Medical Modelling, 2008, 5, 4.	2.1	103
63	Modelling sexually transmitted infections: less is usually more for informing public health policy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 207-208.	0.7	10
64	Coverage Is the Key for Effective Screening of <i>Chlamydia trachomatis </i> Infectious Diseases, 2008, 198, 349-358.	1.9	106
65	A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sexual Health, 2007, 4, 165.	0.4	91
66	Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sexual Health, 2007, 4, 147.	0.4	46
67	Role of saliva use during masturbation in the transmission of Chlamydia trachomatis in men who have sex with men. Epidemiology and Infection, $0$ , , $1-21$ .	1.0	1
68	Assessing the impact of HIV pre-exposure prophylaxis scale-up on gonorrhea incidence among gay and bisexual men in Sydney: a mathematical modelling study. Sexually Transmitted Diseases, 0, Publish Ahead of Print, .	0.8	0